fbpx
Tickets on sale Now!
Over 3 days hear from world experts as we grapple with the problems around patient access, guidelines and supply.

Symposium Events

Australian Medicinal Cannabis Course
 9am-5pm | Thurs 21st | $100
 

Australia’s first medical cannabis course, designed for health care practitioners, by health care practitioners.

Written & Presented by Dr David Caldicott

‘High As Mike’ World Premiere
 7.30pm | Fri 22nd | $20
 

Join us for the world premiere of the feature film ‘High as Mike’. Mike has a brain tumour that will eventually rob him of his sight. In this film Mike goes on a cycling road trip to explore the stagnation of medical cannabis prescription in Australia.

MORE

High as Mike World Premiere

Friday 22nd March | 7.30pm-9pm

Venue: The Showroom at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW

 

Details:

Q&A to follow at 9.00 till 9.45

Tickets are sold separately for those who are not attending the Symposium. Passes must be presented on entry 

Cost: $20 per head

(Tickets included for 3 day & Friday Symposium attendees)

 

Pre-Premiere Drinks & Canapes
 6.30pm | Fri 22nd | $50
 
Dress up and mingle with the Symposium Keynote Speakers, Special Invited Guests and the Production Team for High as Mike at this exclusive ticketed event.
 
Beer or Champagne and canapes served in the Starr’s Room

 

MORE

VIP Pre-premiere Networking Canapes and Champagne

Dress up and mingle with the Symposium Keynote Speakers, Special Invited Guests and the Production Team for High as Mike at this exclusive ticketed event.

Friday 22nd March commencing 6.30pm NSW Time

Beer or Champagne and canapes served in the Starr’s Room at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW.

Cost: $50.00 per person for canapes and one drink on arrival. Additional drinks can be purchased from the bar.

Attendees will be required to purchase their tickets before the event 14/03 for catering purposes. No tickets available on the night. Tickets must be presented upon entry.

Hummingbird Gala Dinner
 7.30pm | Sat 23rd
 

A chance to network, meet hosts and keynote speakers.

Includes 3 course dinner

Exciting announcements still to come!

MORE

Symposium Hummingbird Gala Dinner and Networking Night

Saturday 23rd March | 7.30pm – late

Venue: The Showroom at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW

Dress Code: Cocktail attire

3 Course dinner & drinks

Cost: $150 per head

 Sponsored by Spectrum Cannabis as a major fundraiser for United in Compassion

Keynote Speakers

Dr Graham Gulbransen

In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions…

DETAILS

Dr Graham Gulbransen

MB ChB,  Dip Obs, PGDip Med Sc (Addiction),   FRNZCGP, FAChAM

In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions. Problems addressed include chronic pain, cancer symptoms, anxiety, chronic insomnia and neurological conditions. Most patients have experienced little benefit or adverse effects from conventional treatment or have been told there are no further treatments. Many report that medicinal cannabis offers symptom relief, improved quality of life and most importantly, restores hope.

His part time general practice experience dates from 1983. Much of this work involves assessing and managing addictions and/or chronic pain. He is a FRNZCGP.

Graham completed his Fellowship of the Australasian Chapter of Addiction Medicine (FAChAM) in 2008. As an Addiction Specialist he manages problems such as alcohol and drug withdrawal, opioid substitution treatment, medication for chronic pain and he writes addiction assessments.

David Meiri, PhD

Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research…

DETAILS

David Meiri, PhD

Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research

David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri’s scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on the role of the GEF-H1 protein in tumor invasion and metastasis. During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and succeeded within a very short time frame to receive worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs) and small GTPases. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.

Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.

In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.

Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.

Cam Battley

Cam Battley is Chief Corporate  Officer of Aurora Cannabis, one  of  the world’s largest and fastest growing cannabis companies. A passionate spokesperson for the medical cannabis industry, Cam started with Aurora Cannabis in March 2016…

DETAILS

Cam Battley

Chief Corporate Officer

Aurora Cannabis Inc.

Cam Battley is Chief Corporate Officer  of  Aurora Cannabis, one of the world’s largest and fastest growing cannabis companies. A passionate spokesperson for the medical cannabis industry, Cam started with Aurora Cannabis in March 2016 and has been a key driver to Aurora’s emergence as a global leader.

As a senior healthcare industry leader and strategist with more than 20 years of international experience, Cam is the lead external-facing executive of Aurora, responsible for establishing and managing relationships with shareholders, analysts, media, regulators, governments, and other companies and organizations operating in the cannabis sector. He also chairs the Executive Committee, acts as liaison with the Board, and ensures organizational alignment across the Company’s operations, domestic and international.

Cam is a member of the Board of Directors of Cannabis Canada, the trade association of Licensed Producers. With a background as a health sector management consultant, he brings experience in government, health- care NGOs, and the biopharmaceutical industry.

Prior to joining Aurora, Cam was Vice President of Communications and Corporate Development for Bedrocan Canada, an experienced world-wide producer of legal cannabis. During his time there, Cam was the primary spokesperson and responsible for media, external communications, investor relations, business development, government relations, and physician and patient initiatives. Cam’s leadership generated significant media coverage for Bedrocan.

In 1997, Cam founded Health Strategy Group, an international management consultancy with clients ranging from health professional and patient NGOs, to innovative and generic pharmaceutical firms, and biotechnology and medical device companies. While there, Cam established himself as an expert speaker and communicator and was retained to provide media training for executives and health professionals throughout the industry.

Before founding Health Strategy Group, Cam was Vice President, Creative, of Veritas Communications. Under Cam’s leadership, Veritas grew from six to 24 employees, becoming Canada’s largest health care communications firm.

Dr Donald I. Abrams, MD

Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco…

DETAILS

Dr Donald I. Abrams, MD

Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco.

He has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. He received an A.B. in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977.

After completing an Internal Medicine residency at the Kaiser Foundation Hospital in San Francisco, he became a fellow in Hematology/Oncology at the Cancer Research Institute of the University of California, San Francisco in 1980. He was one the original clinician/investigators to recognize and define many early AIDS-related conditions.

He has long been interested in clinical trials of complementary medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997 he received funding from the National Institute on Drug Abuse to conduct a clinical trial of the short-term safety of cannabinoids in HIV infection. Subsequently he was granted funds by the University of California Center for Medicinal Cannabis Research to conduct a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal.

His last NIH-funded trials investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain and a study of vaporized THC:CBD cannabis in patients with Sickle Cell disease. 

He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website.

He was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017.

Jeffrey Hergenrather

Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999…

DETAILS

Jeffrey Hergenrather, MD

Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999. 

His medical experience includes 26 years in emergency medicine and private general practice that includes the use of cannabis since 1977. He continues in an active consultation practice in northern California with face-to-face, telephone, and on-line consultations for the use of cannabis as medicine.

Ethan Russo, MD

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Director of Research and Development of the International Cannabis and Cannabinoids Institute…

DETAILS

Ethan Russo, MD

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science

ICCI is a “center of excellence” comprised of a consortium of international academic institutions and private companies dedicated to promotion of medical cannabis research and industrial hemp nutrition and husbandry.

Previously, he was Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com).

He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru.

He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard, and Johns Hopkins University.

He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over fifty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions.

He has consulted or lectured on these topics in 39 US states and Canadian provinces and 39 countries.

Dr. Mark A. Ware

Dr. Mark Ware is currently the Chief Medical Officer of Canopy Growth Corporation. He previously served as Director of Clinical Research of the Alan Edwards Pain Management Unit…

DETAILS

Dr. Mark A. Ware

Dr. Mark A. Ware MBBS MRCP(UK) MSc

Dr. Mark Ware is currently the Chief Medical Officer of Canopy Growth Corporation. He has taken a leave of absence as Associate Professor in Family Medicine and Anesthesia at McGill University from July 2018 to work in this capacity.

He previously served as Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre for over 10 years, and was the Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids since 2007.

He has served as co-director of the FRQS-supported Quebec Pain Research Network, and sat on the executive management team of the Alan Edwards Centre for Research on Pain at McGill University. His research has been funded and supported by CIHR, FRQS, private foundations and pharmaceutical companies.

He has published over 100 papers on cannabis and pain research in academic journals, has written 6 book chapters, and has given hundreds of lectures to health professionals and the public on cannabis over the last 20 years. He has served as a consultant to several large corporate and academic research programs internationally. He has advised the Canadian federal government on cannabis policy since 2001, and 2016, he served as the vice chair of the Federal Task Force on the Legalization and Regulation of Cannabis in Canada.

A/Prof Mehdad Nikfaryam

MD, PhD, FRACS from the Austin health, University of Melbourne will speak on “The role of cannabinoids in the treatment of pancreatic cancer”. He has over 150 peer-reviewed publications and has contributed to leading surgical texts…

DETAILS

A/Prof Mehdad Nikfaryam

MD, PhD, FRACS

Austin health, University of Melbourne

“The role of cannabinoids in the treatment of pancreatic cancer”

Background:  Advanced and minimally invasive liver, pancreatic and biliary surgeon with a focus on pancreatic cancer research.  Laboratory head of pancreatic cancer biology group. Clinical research: Advanced and minimally invasive pancreatic resection techniques.  Borderline resectable pancreatic cancers. Neoadjuvant and adjuvant chemotherapy trials.  Brachytherapy for treatment of pancreatic cancer. Enhanced post -operative recovery techniques.  Fluid sparing therapies in pancreatic surgery. Familial pancreatic cancer screening.

Basic Research: Mouse models of pancreatic cancer. K-ras targeted therapies. Role of P-21 Kinase in the development and progression of pancreatic cancer.  Novel therapies for the treatment of pancreatic cancer including use of Cannabis

Contribution to the field of research: I have over 150 peer-reviewed publications. I have written one book and have contributed 4 book chapters in leading surgical texts. I have publications in the highest ranked surgical journals that include Annals of Surgery, British Journal of Surgery, World Journal of Surgery and Annals of Surgical Oncology. I have co-authored five publications in Nature and two in Cancer Letters. I have had 40+ international presentations and 2000+ listed citations relating to my published work. I am a member of Victorian Integrated Cancer Services, Cancer Council and Victorian State Government committees developing guidelines to improve patient outcomes with pancreatic cancer.

lpbsurgery.com

David Bearman

One of the most clinically knowledgeable physicians in the U.S. in the field of medicinal marijuana. He has spent 40 years working in substance and drug abuse treatment and prevention programs…

DETAILS

David Bearman M.D.

 

One of the most clinically knowledgeable physicians in the U.S. in the field of medicinal marijuana. He has spent 40 years working in substance and drug abuse treatment and prevention programs. Dr. Bearman was a pioneer in the free and community clinic movement. His career includes public health, administrative medicine, provision of primary care, pain management and cannabinology.

His almost 40 year professional experience in the drug abuse treatment and prevention field includes being the Co-Director of the Haight-Ashbury Drug Treatment Program, being a member of Governor Reagan’s Inter Agency Task Force on Drug Abuse, a member of both the Santa Barbara and the San Diego County Drug Abuse Technical Advisor Committees, and a consultant to Hoffman-LaRoche, Santa Barbara County Schools and the National PTA. He has been recognized by the Santa Barbara Medical Society with the Humanitarian Recognition Award.

Dr. Bearman is also the author of Drugs Are NOT the Devil’s Tools: How Discrimination and Greed Created a Dysfunctional Drug Policy and How It Can Be Fixed in 2 volumes.

Plus many more speakers to be announced

Full program coming soon

What's Included

Symposium Entry

Prices start at $99

Friday 22nd Pass:

  • Keynote speakers
  • ‘High as Mike’ Premiere
  • Fully catered

Saturday 23rd Pass

  • Keynote speakers
  • Fully catered

Sunday 24th Pass

  • Keynote speakers
  • Fully catered
 

3 Day Pass 

  • Access to all 3 days of keynote speakers
  • ‘High as Mike’ Premiere
  • Fully catered
 
Not included: Hummingbird Gala Dinner & Australian Medicinal Cannabis Course. Please add tickets to your cart if you’d like to attend.

Special Events

Australian Medicinal Cannabis Course

$100pp

Presented by Dr David Caldicott

Course:

  • The Australian history of medicinal cannabis
  • The endocannabinoid system
  • The pharmacology of cannabinoid medicine
  • The practicalities of dosing
Included:
  • Access to industry trade display
  • CDC points (coming soon)
  • Fully catered

Hummingbird
Gala Dinner

$150pp

A chance to network, meet hosts and keynote speakers.

Includes 3 course dinner.

Tickets are available individually or as a full table.

For full table bookings please enquire.

'High as Mike' Premiere

$20pp

The world premiere of ‘High as Mike’ – a documentary exploring the problems facing patient access to medicinal cannabis.

Screening included in 3 Day & Friday Symposium Entry

or purchase ticket separate

Pre-Premiere Canapes & Drinks

$50pp

An exclusive pre-premiere drinks & canapes and a networking opportunity. 

Mingle with Keynote speakers, special invited guests and the production team for ‘High as Mike’

Includes:

  • One drink
  • Canapes

Sponsors

Sponsor this event! Help us in our fight for compassion